Institutional Investors Pounced on Morphic Therapeutic Shares Just Before Eli Lilly Deal
The biotechnology sector has long been a playground for high-stakes acquisitions, but the recent movement surrounding Morphic Therapeutic offers a masterclass in
by 
Josh Weiner
Josh Weiner